# ixCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ixcell

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.ixcellbio.com
- Latest round: Series B (Aug 4, 2025)
- Investors on record: 5

## About

Founded in 2013 and based in Shanghai, china, ixCell operates primarily in the field of cell therapy by developing innovative cell-based pharmaceuticals. In August 2025, ixCell closed a Series B+ funding from returning investors Huaou Equity Investment and Capitallink, with participation from new investors Jebel Pharm and Shandong Sito Bio-technology Co., Ltd.
The company develop cell therapies, including mesenchymal stem cell therapies, induced pluripotent stem cell (iPSC) products, and immunotherapy solutions. These therapies are designed to address medical conditions such as knee osteoarthritis, stroke, pulmonary fibrosis, autoimmune diseases, and solid tumors. 
The company generates revenue through clinical-grade products and services tailored for the biotechnology and pharmaceutical sectors.

## Funding rounds

- Series B, Aug 4, 2025 — Huaou Equity Investment, Shandong Sito Bio-technology Co., Ltd., Capitallink, Jebel Pharm, Lingzhen Capital

## Investors

- Huaou Equity Investment — Series B
- Shandong Sito Bio-technology Co., Ltd. — Series B
- Capitallink — Series B
- Jebel Pharm — Series B
- Lingzhen Capital — Series B